8-K: Merck Reports Strong Q3 2024 Results Driven by Keytruda and New Launches

Merck's third-quarter 2024 results show a 4% increase in worldwide sales, reaching $16.7 billion, with a 7% increase excluding foreign exchange impacts.

Summary

• Merck announced its financial results for the third quarter of 2024, with total worldwide sales reaching $16.7 billion, a 4% increase compared to the same period in 2023.
• Excluding the impact of foreign exchange, sales grew by 7%.
• Key growth drivers included increased sales of KEYTRUDA, which grew 17% to $7.4 billion, and new product launches like WINREVAIR, which recorded $149 million in sales.
• Animal Health sales also saw a 6% increase, reaching $1.5 billion.
• GAAP earnings per share (EPS) were $1.24, while non-GAAP EPS was $1.57, both impacted by a net charge of $0.79 per share related to business development transactions.
• The company has narrowed its full-year 2024 sales outlook to between $63.6 billion and $64.1 billion and expects non-GAAP EPS to be between $7.72 and $7.77.
• These figures include a net negative impact of $0.24 per share related to recent business development transactions.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While sales growth is positive, the significant impact of business development charges on EPS and the lowered full-year EPS outlook temper the overall sentiment. The pipeline advancements and strategic acquisitions are positive, but the financial results are not as strong as they could be.

Positives

• Strong sales growth in KEYTRUDA and Animal Health.
• Successful launch of WINREVAIR with significant sales and regulatory approvals.
• Positive clinical trial results for CAPVAXIVE and clesrovimab.
• Advancements in the oncology pipeline with multiple data presentations at ESMO Congress 2024.
• Strategic acquisitions, including CN201 (MK-1045), to expand the pipeline.
• Narrowed full-year sales outlook, indicating confidence in performance.

Negatives

• GAAP and non-GAAP EPS decreased due to significant charges related to business development transactions.
• Lower sales of JANUVIA, JANUMET, GARDASIL/GARDASIL 9, and LAGEVRIO impacted overall revenue growth.
• GARDASIL/GARDASIL 9 sales declined in China due to reduced demand.
• Research and development expenses increased significantly due to acquisitions and higher clinical development spending.
• The full-year non-GAAP EPS outlook was lowered due to the impact of business development transactions.

Risks

• The company faces risks related to foreign exchange fluctuations, particularly the devaluation of the Argentine peso.
• There are challenges related to generic competition for some of its products, such as JANUVIA and BRIDION.
• The company is exposed to risks associated with new product development and regulatory approvals.
• The company's financial results are subject to the impact of pharmaceutical industry regulation and healthcare legislation.
• The company is exposed to litigation, including patent litigation, and/or regulatory actions.

Future Outlook

Merck has narrowed its full-year 2024 sales outlook to between $63.6 billion and $64.1 billion and expects non-GAAP EPS to be between $7.72 and $7.77. The outlook includes a net negative impact of $0.24 per share related to recent business development transactions and does not assume any additional significant potential business development transactions.

Management Comments

• Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond, said Robert M. Davis, chairman and chief executive officer, Merck.
• Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a more diversified portfolio to drive growth.
• I continue to remain confident in the strength of our business and our ability to execute, and I want to thank our colleagues across the globe for their focus and commitment as we work to create lasting value for patients, shareholders and all our stakeholders.

Industry Context

Merck's Q3 results reflect the ongoing demand for its key products like KEYTRUDA and the successful launch of new therapies like WINREVAIR. The company's focus on oncology and vaccines aligns with broader industry trends in these high-growth areas. The strategic acquisitions and collaborations also indicate a proactive approach to pipeline expansion and diversification, which is crucial for maintaining a competitive edge in the biopharmaceutical industry.

Comparison to Industry Standards

• Merck's 17% growth in KEYTRUDA sales is strong compared to other immuno-oncology drugs, such as Bristol Myers Squibb's Opdivo, which has seen more modest growth in recent quarters.
• The launch of WINREVAIR and its $149 million in sales is a positive sign, especially when compared to other recent launches in the pulmonary arterial hypertension space, where uptake can be slow.
• The 6% growth in Animal Health is in line with the industry average, but the 11% growth excluding foreign exchange is a strong result.
• The significant increase in R&D expenses, driven by acquisitions, is a common strategy among large pharmaceutical companies looking to bolster their pipelines, similar to recent moves by companies like AbbVie and Pfizer.
• The narrowing of the full-year sales outlook is a positive sign, indicating confidence in the company's performance, which is a contrast to some other companies that have lowered guidance due to market pressures.

Stakeholder Impact

• Shareholders may be concerned about the lower EPS and reduced full-year outlook.
• Patients will benefit from the continued development and availability of new medicines and vaccines.
• Employees are recognized for their focus and commitment to creating value.
• Customers will have access to a broader range of products and services.
• Suppliers and creditors will continue to engage with a financially stable company.

Next Steps

• Merck will continue to focus on the commercialization of WINREVAIR in the U.S. and Europe.
• The company will work to obtain reimbursement for WINREVAIR in other EU countries.
• Merck will continue to advance its pipeline candidates through clinical trials and regulatory approvals.
• The company will continue to evaluate potential business development opportunities.

Key Dates

Keywords

KEYTRUDA, WINREVAIR, CAPVAXIVE, Animal Health, Oncology, Vaccines, Pharmaceuticals, Financial Results, EPS, Sales, Acquisition, R&D, Business Development